Certain Plant-Based Foods May Cut Crohn's Disease Risk
A high combined intake of fruits, vegetables, legumes, and potatoes was associated with a reduced risk for Crohn's disease — driven largely by specific foods such as apples or pears, bananas, mushrooms, and onions or garlic. Alternatively, a high intake of potatoes was associated with an increased risk for ulcerative colitis.
METHODOLOGY:
The International Organization for the Study of Inflammatory Bowel Disease recommends eating more fruits and vegetables for their fiber benefits, but current guidelines do not distinguish between subcategories despite their differing compositions and potential effects on inflammatory bowel disease (IBD) risk.
Researchers analyzed data of 341,519 participants without IBD (mean age, 52.1 years; 70% women) from a popular European cohort to evaluate how consumption of individual fruits, vegetables, legumes, and potatoes influenced the risk for Crohn's disease and ulcerative colitis.
At baseline, validated food frequency questionnaires were used to assess dietary intake of fruits, vegetables, legumes, and potatoes (including other tubers).
Participants in the lowest vs highest quartiles had median daily intakes of 291.6 vs 840.9 g/d of combined fruits, vegetables, legumes, and potatoes; 17.0 vs 100.3 g/d of apples/pears; 6.6 vs 14.0 g/d of bananas; 2.1 vs 6.2 g/d of mushrooms; 4.1 vs 11.9 g/d of onions or garlic; and 64.7 vs 82.1 g/d of potatoes.
TAKEAWAY:
The median follow-up period was 13.4 years, during which 149 participants developed Crohn's disease and 379 developed ulcerative colitis.
A higher combined intake of fruits, vegetables, legumes, and potatoes was associated with a lower risk of developing Crohn's disease (highest vs lowest quartile; adjusted hazard ratio [aHR], 0.44; 95% CI, 0.26-0.76) but not ulcerative colitis (aHR, 1.07; 95% CI, 0.76-1.50).
A subsequent post hoc analysis showed that the pooled intake of apples or pears, bananas, mushrooms, and onions or garlic was linked to a comparable risk reduction for Crohn's disease as total fruit, vegetable, legume, and potato intake (highest vs lowest quartile; pooled aHR, 0.58; 95% CI, 0.33-1.02).
However, a higher intake of potatoes was associated with a higher risk of developing ulcerative colitis (highest vs lowest quartile; aHR, 1.51; 95% CI, 1.05-2.17).
IN PRACTICE:
'In conclusion, we found that high combined intake of fruits, vegetables, legumes, and potatoes is associated with a lower risk of developing CD but not UC. This was particularly apparent for apple/pear, banana, mushrooms, and onion/garlic intakes. A higher risk of UC was observed for a higher intake of potatoes,' the authors of the study wrote.
SOURCE:
This study was led by Antoine Meyer, MD, PhD, Université Paris-Saclay, Villejuif, France. It was published online in the American Journal of Gastroenterology.
LIMITATIONS:
This study relied on food frequency questionnaires measured only at baseline, which may not have fully captured dietary changes over time. The mostly older, female population may not have represented the broader European or younger populations. As with all observational studies, residual confounding from unmeasured factors could not be ruled out.
DISCLOSURES:
The cohort was supported by the International Agency for Research on Cancer, the Department of Epidemiology and Biostatistics, School of Public Health, and other sources. Some authors declared receiving speaker fees, grants, consulting fees, and travel support from various pharmaceutical companies.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
an hour ago
- Gizmodo
New Research Debunks Myth That Brain Cells Stop Growing After Childhood
You've probably heard the old canard that new brain cells simply stop forming as we become adults. But research out today is the latest to show that this isn't really true. Scientists in Sweden led the study, published Thursday in Science. They found abundant signs of neural stem cells growing in the hippocampus of adult brains. The findings reveal more about the human brain as we get older, the researchers say, and also hint at potential new ways to treat neurological disorders. 'We've found clear evidence that the human brain keeps making new nerve cells well into adulthood,' study co-author Marta Paterlini, a neuroscientist at the Karolinska Institute in Stockholm, told Gizmodo. This Is What Your Brain Looks Like When You Solve a Problem This isn't the first paper to chip away at the idea of new neurons ceasing to form in adulthood (a concept not to be confused with general brain development, which does seem to reach maturity around age 30). In 2013, study researcher Jonas Frisén and his team at the Karolinska Institute concluded that substantial neuron growth—also known as neurogenesis—occurs throughout our lives, albeit with a slight decline as we become elderly. But there's still some debate ongoing among scientists. In spring 2018, for instance, two different studies of neurogenesis published a month apart came to the exact opposite conclusion. The researchers were hoping to settle one particular aspect of human neurogenesis in adults. If we do keep growing new neurons as we age, then we should be able to spot the cells that eventually mature into neurons, neural progenitor cells, growing and dividing inside the adult brain. To look for these cells, the team analyzed brain tissue samples from people between the ages of 0 and 78 using relatively new advanced methods. These methods allowed them to figure out the characteristics of brain cells on an individual level and to track the genes being expressed by a single cell's nucleus. All told, the researchers examined more than 400,000 individual cell nuclei from these samples. And as hoped, they found these progenitor cells along various stages of development in adult brains, including cells just about to divide. They also pinpointed the location within the hippocampus where the new cells appeared to originate: the dentate gyrus, a brain region critical to helping us form certain types of memory. 'We saw groups of dividing precursors sitting right next to the fully formed nerve cells, in the same spots where animal studies have shown adult stem cells live,' said Paterlini, a senior scientist at the Frisén lab. 'In short, our work puts to rest the long-standing debate about whether adult human brains can grow new neurons.' Something Strange Happens to Brains During a Marathon The findings, as is often true in science, foster more questions in need of an answer. Our adult precursor cells seem to have different patterns of gene activity compared to the cells found in pigs, mice, and other mammals with clear evidence of adult neurogenesis, for instance. The researchers also found that some adults' brains were filled with these growing precursors, while others had relatively few. These differences—combined with the team's earlier research showing that adult neurogenesis slows down over time—may help explain people's varying risk of neurological or psychological conditions, the authors say. And likewise, finding a safe way to improve the adult brain's existing ability to grow new cells could help treat these conditions or improve people's recovery from serious head injuries. 'Although precise therapeutic strategies for humans are still being researched, the simple fact that our adult brains can generate new neurons radically changes the way we view lifelong learning, recovery from injury, and the untapped potential of neuronal plasticity,' said Paterlini. There's plenty more to be learned about how our brains change over time. The team is planning to investigate other likely hotspots of neurogenesis in the adult brain, such as the wall of the lateral ventricles (c-shaped cavities found in each of the brain's cerebral hemispheres) and nearby regions. But we can be fairly certain that our neurons keep on growing and replacing themselves into adulthood—at least for some of us.
Associated Press
3 hours ago
- Associated Press
Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook to 2031: United States and China Lead Global Gamma Delta T Cell Therapy Clinical Trials
DUBLIN--(BUSINESS WIRE)--Jul 3, 2025-- The 'Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031" report has been added to offering. Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031 Report Conclusions: Adoptive gamma delta T cell therapy is a novel type of immunotherapy that utilizes a unique subset of T cells to recognize and destroy cancer cells. While typical alpha-beta (aß) T cells identify antigens presented by major histocompatibility complex (MHC) molecules, gamma delta T cells are activated by stress induced ligands and phosphoantigens in an MHC independent fashion. This enables them to detect and target a wide variety of tumor types, including those that are not targeted by conventional immune vigilance. gamma delta T cells possess characteristics of both innate and adaptive immunity, allowing them to have the ability for immediate response and immune memory, which make them particularly good candidates for off-the-shelf adoptive cell therapies. In cancer, gamma delta T cells are under investigation for their potential to destroy malignant cells without the requirement of tumor-specific antigens or genetic modifications, which are technically demanding and expensive. Their intrinsic cytotoxicity, along with the possibility of allogeneic utilization (from healthy donors), provides access to the availability of mass producible, inexpensive therapies. The majority of clinical research and development to date has been in hematological malignancies, where they have been especially promising. Gamma delta T cells are able to penetrate the bone marrow and other lymphoid organs and exert tumor effects there through cytokine release, direct cytotoxicity, and changing the microenvironment of the tumor. The demand for novel cancer therapies is pressing, especially in blood cancers like acute myeloid leukemia (AML), which tend to relapse or are resistant to conventional therapies. Options for patients who relapse following remission or who have residual disease (MRD) are limited, and prognosis is usually poor. Gamma delta T cell therapies are in a unique position to bridge this gap, providing a potentially effective, safe, and off-the-shelf product that can be delivered without the logistical issues of autologous T cell therapies, including manufacturing hold-ups or patient variability. TC Biopharm is leading the way in clinical development in this area. The company's most advanced product candidate, OmnImmune (formerly TCB-002), is in a pivotal Phase 2/3 trial for AML. OmnImmune is an allogeneic gamma delta T cell therapy engineered to quickly target and destroy cancer cells while avoiding damage to normal tissue. This clinical program is one of the most advanced in the global gamma delta T cell pipeline, highlighting TC Biopharm's growing leadership within the domain. Besides OmnImmune, the company has a number of other gamma delta T cell candidates in development for various cancer indications. One of the most significant recent advances from TC Biopharm is the development of its candidate TCB008, which is under investigation in the Phase 2 ACHIEVE trial. The firm reported in June 2025 that the first patient in Cohort B, who had relapsed previously with detectable MRD, reached complete molecular remission following two doses. A lack of detectable NPM1 transcripts after treatment signifies a profound and lasting response, which identifies TCB008 as a promising post-remission therapy for blood cancers. This achievement demarcates the potent, targeted immune function of gamma delta T cells and substantiates their role as a new therapeutic strategy. Globally, most of the research studies on gamma delta T cells remains on hematologic malignancies, and there are fewer programs directed at solid tumors. This is partly a result of the more sophisticated microenvironments and the immune evasion mechanisms utilized by solid cancers. However, attempts are being made to apply gamma delta T cell treatments to these more difficult contexts. Geographically, US-based players dominate the gamma delta T cell therapy market, followed by increasing numbers of Chinese firms. These regions have made heavy investment in cell therapy facilities and technology, facilitating quicker translation from bench to bedside. Moving forward, the prospects for gamma delta T cell therapy are bright but will necessitate continued clinical validation, most importantly in solid tumors. With advances in manufacturing technologies and biomarker-driven strategies, the use of gamma delta T cells may extend to more types of cancers. With leaders such as TC Biopharm at the forefront, the field is on track to provide life changing treatments for critical unmet needs in cancer domain. Company Coverage: Key Topics Covered: 1. Introduction To Gamma Delta T Cell Therapy 1.1 Emerging Role of T Cell Based Immunotherapies 1.2 Overview of Gamma Delta T Cell Therapy 1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies 2. Role of Gamma Delta T Cells in Cancer 2.1 Gamma Delta T Cells in Cancer Progression 2.2 Anti Tumor Activity of Gamma Delta T Cells 2.3 Adopted Approaches for Gamma Delta T Cell Therapy 3. Advanced Combination Strategies In Gamma Delta T Cell Therapy 4. Gamma Delta T Cell Therapy Market Overview 4.1 Current Market Scenario 4.2 Future R&D & Commercial Opportunities 4.3 Market Potential of Gamma Delta T Cell Therapy Market 4.4 Technology Platforms For Gamma Delta T Cell Therapy 4.5 Favorable Market Growth Parameters 4.6 Key Challenges To Overcome For Future Growth 5. Global Gamma Delta T Cell Therapy Clinical Trials Overview 5.1 By Phase 5.2 By Country 5.3 By Company 5.4 By Indication 5.5 By Priority Status 6. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase 6.1 Research 6.2 Preclinical 6.3 Phase I 6.4 Phase I/II 6.5 Phase II 6.6 Phase II/III 7. Gamma Delta T Cell Therapy In Leukemia 7.1 Ongoing Clinical Research & Development Trends 7.2 Future Market Opportunity of Gamma Delta T Cells In Leukemia 8. Gamma Delta T Cell Therapy In Lung Cancer 8.1 Ongoing Clinical Research & Development Trends 8.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Lung Cancer 9. Gamma Delta T Cells In Breast Cancer 9.1 Ongoing Clinical Research & Development Trends 9.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Breast Cancer 10. Gamma Delta T Cells in Colorectal Cancer 10.1 Ongoing Clinical Research & Development Trends 10.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer 11. Gamma Delta T Cells In Pancreatic Cancer 11.1 Ongoing Clinical Research & Development Trends 11.2 Future Market Potential of Gamma Delta Therapy In Pancreatic Cancer 12. Gamma Delta T Cells In Lymphoma 12.1 Ongoing Clinical Research & Development Trends 12.2 Future Market Potential of Gamma Delta Therapy In Lymphoma 13. Gamma Delta T Cell Therapy In Brain Tumors 13.1 Research & Development In Brain Tumors 13.2 Future Market Potential of Gamma Delta Therapy In Brain Tumors 14. Gamma Delta T Cell Therapy In Head & Neck Cancer 14.1 Research & Development In Head & Neck Cancer 14.2 Future Market Potential of Gamma Delta Therapy In Head & Neck Cancer 15. Competitive Landscape 15.1 Acepodia 15.2 Adicet 15.3 Appia Bio 15.4 Cytomed Therapeutics 15.5 Century Therapeutics 15.6 Expression Therapeutics 15.7 Immatics 15.8 IN8bio 15.9 JY BioMed 15.10 Legend Biotech 15.11 Luminary Therapeutics 15.12 PhosphoGam 15.13 Takeda 15.14 TC Biopharm 15.15 ViGenCell For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH GENETICS PHARMACEUTICAL ONCOLOGY SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 07/03/2025 12:19 PM/DISC: 07/03/2025 12:19 PM
Medscape
3 hours ago
- Medscape
Fast Five Quiz: Management of GPA
Granulomatosis with polyangiitis (GPA) is a variant of anti-neutrophil cytoplasmic antibody ( ANCA)-associated vasculitis that most commonly presents with proteinase 3 (PR3) serology and distinct clinical features that necessitates swift identification and therapeutic intervention. Prompt treatment plays a crucial role in minimizing permanent organ damage, particularly in the renal and pulmonary systems. What do you know about the management of GPA? Check your knowledge with this quick quiz. The latest guidelines from the Kidney Disease Improving Global Outcomes (KDIGO) and European Alliance of Associations for Rheumatology (EULAR) both recommend initiating immunosuppressive therapy in patients with suspected PR3 positive ANCA vasculitis, which is indicative of GPA, even if clinicians are still awaiting biopsy results. Further, EULAR specifically acknowledges that collecting biopsies might not be feasible for each patient with ANCA vasculitis and treatment should 'not be delayed while awaiting histological information.' Learn more about biopsy for GPA. KDIGO recommends maintaining therapeutic intervention for 18 months to 4 years following successful remission, which is similar to the EULAR guidelines recommending maintenance therapy for 24-48 months in patients with GPA. They also state, 'longer duration of therapy should be considered in relapsing patients or those with an increased risk of relapse, but should be balanced against patient preferences and risks of continuing immunosuppression.' Learn more about remission maintenance in GPA. Infection is a significant concern in ANCA vasculitis, especially regarding immunosuppressive therapies including glucocorticoids that are used to manage the clinical manifestations of the disease. Recent research has shown that chronic nasal carriage of S aureus is significantly higher in patients with the GPA subtype; it has also been shown to be associated with increased endonasal activity and risk for relapse. Although M catarrhalis, H influenzae, and S pneumoniae do not appear to have a specific association with GPA, data have shown that infection is among the most common causes of death in GPA. Learn more about infection in GPA. Data indicate that the GPA subtype is an independent risk factor for disease recurrence. Additionally, KDIGO also considers lower serum creatinine, more extensive disease, PR3 histology (which is associated with higher relapse rates than MPO-positive disease commonly seen in MPA) and ear, nose, and throat involvement as 'baseline factors' for disease recurrence. Factors after diagnosis include history of relapse, ANCA positivity at the end of induction, and rise in ANCA. Treatment-related relapse factors include lower cyclophosphamide exposure, immunosuppressive withdrawal, and glucocorticoid withdrawal. Learn more about prognosis in GPA. To ensure disease does not recur into the transplanted tissue, KDIGO specifically recommends delaying kidney transplantation until patients have achieved complete clinical remission for at least 6 months. Further, ANCA positivity or negativity should not factor into this decision, with KDIGO stating, 'the persistence of ANCA should not delay transplantation.' Although a serum creatinine of > 4 mg/dL is a significant predictor of relapse, guidelines recommend considering combination of a monoclonal antibody and an alkylating agent for this indication. Similarly, induction and maintenance of dialysis should also be done under various separate conditions. Learn more about kidney transplantation for GPA. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.
